Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 2003

View Archived Issues

Schering sells stake in Oy Leiras to Nycomed

Pfizer to continue Pharmacia's collaboration with Vicuron

Diabact licenses Rapinyl to Kyowa Hakko

Xoma provides review of results for the first quarter

MCH antagonists in early development for obesity and related disorders at Schering-Plough

Schering-Plough researchers design new adenosine A2A antagonists for Parkinson's disease

Neurogen describes new NPY Y5 receptor modulators in recent patent literature

New IMPDH inhibitors, their preparation and use reported by Celltech R&D

Novel isoflavones with utility in hormone balance disorders, cancer, inflammation, etc.

New pyrrolidine-based FTase inhibitors under study at Wyeth

Applied Research Systems presents a novel series of prostanoid EP2/EP4 modulators

Antibacterial isoxazoles prepared and tested at AstraZeneca

Boehringer Ingelheim patent covers novel cytokine production inhibitors

Lipid-lowering effects of ezetimibe in hypercholesterolemia

Effective use of anidulafungin in patients with invasive candidiasis

Strong bactericidal activity found for oritavancin against clinical isolates

Aripiprazole is safe and improves psychotic symptoms in Alzheimer's dementia

New data on vardenafil reported at the American Geriatrics Society meeting

Milestone achieved in PROCARDIS consortium study

Bioenvision signs agreement with Penn for clofarabine

FDA approval to export DB-289 for malaria trial in Thailand

Advisory committee recommends approval of Xolair

Important European launch reported for Hepsera

Electrophysiological effects of drug selectively targeting I(Kur) in myocytes from AF patients

Butanediol esters as potential new bone resorption inhibitors

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...